Ulas Babacan O, Hasbek Z, Terzi H
Mol Imaging Radionucl Ther. 2025; 34(1):26-30.
PMID: 39918004
PMC: 11827519.
DOI: 10.4274/mirt.galenos.2024.78557.
Almodovar Diaz A, Alouch S, Chawla Y, Gonsalves W
Blood Lymphat Cancer. 2024; 14:71-87.
PMID: 39664714
PMC: 11631777.
DOI: 10.2147/BLCTT.S490021.
Yao B, Liu Y, Wu Y, Mao S, Zhang H, Jiang L
PeerJ. 2024; 12:e18391.
PMID: 39512310
PMC: 11542560.
DOI: 10.7717/peerj.18391.
Xu Z, Yang S, Zhu L, Wan X, Xu H, Chen H
Transl Cancer Res. 2024; 13(9):5149-5156.
PMID: 39430820
PMC: 11483438.
DOI: 10.21037/tcr-24-511.
Huang Y, Wang C, Wang H, Liu H, Zhou L
Heliyon. 2024; 10(13):e34111.
PMID: 39055831
PMC: 11269926.
DOI: 10.1016/j.heliyon.2024.e34111.
GLP and G9a histone methyltransferases as potential therapeutic targets for lymphoid neoplasms.
Silva-Carvalho A, Filiu-Braga L, Bogea G, de Assis A, Pittella-Silva F, Saldanha-Araujo F
Cancer Cell Int. 2024; 24(1):243.
PMID: 38997742
PMC: 11249034.
DOI: 10.1186/s12935-024-03441-y.
Beyond the mouth: Uncovering non-secretory multiple myeloma through oral symptoms.
Isaias P, Costa F, Amorim P, da Silva R, Sousa F, Pereira K
Imaging Sci Dent. 2024; 54(2):211-220.
PMID: 38948192
PMC: 11211024.
DOI: 10.5624/isd.20230257.
Highlighting the role of long non-coding RNA (LncRNA) in multiple myeloma (MM) pathogenesis and response to therapy.
Al-Hawary S, Jasim S, Altalbawy F, Hjazi A, Jyothi S, Kumar A
Med Oncol. 2024; 41(7):171.
PMID: 38849654
DOI: 10.1007/s12032-024-02392-8.
Activated interferon response from DNA damage in multiple myeloma cells contributes to the chemotherapeutic effects of anthracyclines.
Li J, Jia Z, Wang R, Xiao B, Cai Y, Zhu T
Front Oncol. 2024; 14:1357996.
PMID: 38800411
PMC: 11116600.
DOI: 10.3389/fonc.2024.1357996.
Exploring the Impact of Cytogenetic Abnormalities on Treatment Responses and Survival Outcomes in Multiple Myeloma: A Single-Centre Experience of 13 Years of Follow-Up.
Kazgi M, Bayram E, Koseci T, Mete B, Toyran T, Ergin M
Biomedicines. 2024; 12(5).
PMID: 38790976
PMC: 11117921.
DOI: 10.3390/biomedicines12051014.
An Assessment of the Effectiveness and Safety of Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma Patients with Relapsed or Refractory Disease: A Systematic Review and Meta-Analysis.
Pereira R, Bergantim R
Int J Mol Sci. 2024; 25(9.
PMID: 38732213
PMC: 11084236.
DOI: 10.3390/ijms25094996.
Prognostic significance of β2-microglobulin decline index in multiple myeloma.
Zhang T, Lin Z, Zheng Z, Wang Q, Zhou S, Zhang B
Front Oncol. 2024; 14:1322680.
PMID: 38562177
PMC: 10982376.
DOI: 10.3389/fonc.2024.1322680.
Impact of Genetic Polymorphisms in NF-ĸB2 and TRAF3 Genes on Response to Bortezomib-Based Therapy in Multiple Myeloma Patients.
Sood N, Hamide A, Dubashi B, Nisha Y, Mathaiyan J, Munirajan A
Asian Pac J Cancer Prev. 2024; 25(3):829-837.
PMID: 38546066
PMC: 11152374.
DOI: 10.31557/APJCP.2024.25.3.829.
Role of Non-Coding RNAs in Diagnosis, Prediction and Prognosis of Multiple Myeloma.
Dubaj M, Bigosinski K, Dembowska A, Mlak R, Szudy-Szczyrek A, Malecka-Massalska T
Cancers (Basel). 2024; 16(5).
PMID: 38473390
PMC: 10931522.
DOI: 10.3390/cancers16051033.
A Novel Necroptosis-Related Signature Can Predict Prognosis and Chemotherapy Sensitivity in Multiple Myeloma.
Jiang J, Yao F, Liu J, Wang X, Huang B, Zhong F
Technol Cancer Res Treat. 2024; 23:15330338241232554.
PMID: 38361483
PMC: 10874153.
DOI: 10.1177/15330338241232554.
An overview of multiple myeloma: A monoclonal plasma cell malignancy's diagnosis, management, and treatment modalities.
Abduh M
Saudi J Biol Sci. 2024; 31(2):103920.
PMID: 38283805
PMC: 10818257.
DOI: 10.1016/j.sjbs.2023.103920.
Stromal alterations in patients with monoclonal gammopathy of undetermined significance, smoldering myeloma, and multiple myeloma.
Bogun L, Koch A, Scherer B, Fenk R, Maus U, Bormann F
Blood Adv. 2024; 8(10):2575-2588.
PMID: 38241490
PMC: 11145751.
DOI: 10.1182/bloodadvances.2023011632.
Circular RNA circXPO1 Promotes Multiple Myeloma Progression by Regulating miR-495-3p/DNA Damage-Induced Transcription 4 Axis.
Li F, Liu J, Miao J, Hong F, Liu R, Lv Y
DNA Cell Biol. 2023; 43(1):39-55.
PMID: 38079253
PMC: 10825292.
DOI: 10.1089/dna.2023.0288.
5-Aza-2'-Deoxycytidine Alters the Methylation Profile of Bortezomib-Resistant U266 Multiple Myeloma Cells and Affects Their Proliferative Potential.
Luczkowska K, Kulig P, Rusinska K, Baumert B, Machalinski B
Int J Mol Sci. 2023; 24(23).
PMID: 38069103
PMC: 10706146.
DOI: 10.3390/ijms242316780.
Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulation.
Jin S, Li B, Zhang B, Gao X, Jia X, Xu L
Acta Biochim Biophys Sin (Shanghai). 2023; 55(12):1884-1891.
PMID: 38009004
PMC: 11294055.
DOI: 10.3724/abbs.2023260.
